Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Shutters Research Unit Asubio amid R&D Rejig
February 13, 2017
- Novartis Seeks Pediatric CML Indication for Tasigna
February 13, 2017
- Bayer Yakuhin Ramping Up Digital Transformation: New President
February 10, 2017
- Harvoni No. 1 Drug in Japan in 2016 with Sales of 296 Billion Yen, More than Any Other Drug Over Past 10 Years: IMS Japan
February 10, 2017
- Sandoz Looks to Double Japan Sales by 2022
February 9, 2017
- Ethical Drug Sales Down 8.2% in December: Crecon
February 8, 2017
- OrphanPacific to Distribute Diazoxide from April
February 7, 2017
- Akihisa Nabeshima to Become Teijin Pharma President
February 7, 2017
- FDA Snubs Daiichi Sankyo’s Nausea Med
February 7, 2017
- ASKA to Absorb Former Actavis JV
February 7, 2017
- Sanofi, Yakult Honsha Link Arms on Zaltrap
February 7, 2017
- Ex-Lilly Exec Tsunaba Tapped as Novartis Japan Chief
February 7, 2017
- Ono Denies Nikkei Report on US Mega Acquisition Plan
February 7, 2017
- Sumitomo Dainippon Sees Blockbuster Potential for Napabucasin
February 6, 2017
- IP High Court Rules in Lilly’s Favor on Alimta Vitamin Therapy Patents
February 6, 2017
- Janssen, Mitsubishi Tanabe to Copromote Stelara for Crohn’s Disease
February 6, 2017
- Eisai to Begin Japan PIII on Fycompa Monotherapy for Partial-Onset Seizures
February 6, 2017
- Bioverativ Japan Launched on Feb. 1
February 3, 2017
- Ono’s Opdivo Sales at 82.6 Billion Yen in April-December
February 3, 2017
- Takeda Wants to Be Global GI Leader in 2025, Not in Acquisition Frenzy Mode: CEO
February 3, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…